Hepatocyte Growth Factor (HGF), the sole ligand for the MET receptor tyrosine kinase, is a critical driver of tumor invasive growth, metastasis, and acquired resistance to targeted therapies (such as EGFR inhibitors). Developing therapeutics that disrupt the HGF/MET axis requires highly characterized reagents that mimic native conformation and glycosylation to ensure clinical translation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HGF drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HGF Active Heterodimer / Single-Chain Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View HGF Products |
| Gene Delivery | HGF Promise-ORF / Lentivirus Full-length ORF for stable cell lines and in vitro expression. |
View HGF Products |
| Benchmark Ab | Anti-HGF Recombinant Antibody (Sequence of Ficlatuzumab / Rilotumumab) Recombinant positive control for ligand-blocking assays. |
View HGF Products |
| Validator | HGF siRNA Set For knockdown verification in functional assays. |
View HGF Products |
| Related Target A | MET The high-affinity receptor for HGF. Crucial for receptor-ligand binding assays and phosphorylation screening. |
View MET Products |
| Related Target B | EGFR HGF/MET activation bypasses EGFR signaling, driving resistance. Essential for combination therapy screening. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Active Heterodimer Conformation | HEK293 expressed recombinant HGF with native proteolytic cleavage, ensuring authentic alpha/beta chain assembly. |
| Heparin-Dependent Binding Verification | High-purity HGF variants with intact heparin-binding domains, verified by theoretical molecular weight and charge profiles. |
| Lack of Controls | Clinical Benchmark Antibodies (Ficlatuzumab/Rilotumumab sequence-verified biosimilars) included. |
| False Positives | Validated siRNA included for target-specific knockdown and specificity checks in cell-based assays. |
Live HGF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HGF therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) to multi-specific biologics and combination regimens. As first-generation therapies reach the clinic, the next wave of R&D is targeting HGF-mediated resistance pathways in solid tumors. Overcoming EGFR-TKI resistance in non-small cell lung cancer (NSCLC) remains a primary therapeutic objective, alongside exploring HGF's regenerative potential in cardiovascular and renal indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | AVEO Oncology, Amgen | Solid Tumors (NSCLC, Head and Neck Cancer) | Ligand-blocking assays requiring native, cleavage-verified HGF heterodimers. |
| Bispecific Antibodies / Fusion Proteins | Johnson & Johnson, Roche | EGFR-mutant NSCLC, Gastric Cancer | Dual-targeting validation requiring high-purity MET and EGFR co-incubation assays. |
| Regenerative Therapeutics (Agonists) | Anges, Helixmith | Critical Limb Ischemia, Diabetic Peripheral Neuropathy | Functional signaling validation using lentivirus-driven MET-overexpressing stable cell lines. |